EZH2 and lymphoma: Treatment with DzNep (EZH2 methyltransferase inhibitor) or ibrutinib increased FAS ligand-mediated apoptosis in lymphoma cell lines by abolishing the EZH2-mediated repression of FAS-AS1 expression, resulting in decreased expression of sFAS [7].